Free Trial

Virax Biolabs Group (VRAX) Short Interest Ratio & Short Volume

Virax Biolabs Group logo
$1.00 -0.02 (-1.92%)
Closing price 07/23/2025 03:55 PM Eastern
Extended Trading
$1.03 +0.03 (+3.16%)
As of 08:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Virax Biolabs Group Short Interest Data

Virax Biolabs Group (VRAX) has a short interest of 131,000 shares, representing 0.91% of the float (the number of shares available for trading by the public). This marks a 529.81% increase in short interest from the previous month. The short interest ratio (days to cover) is 1.0, indicating that it would take 1.0 days of the average trading volume of 1.73 million shares to cover all short positions.

Current Short Interest
131,000 shares
Previous Short Interest
20,800 shares
Change Vs. Previous Month
+529.81%
Dollar Volume Sold Short
$103.71 thousand
Short Interest Ratio
1.0 Days to Cover
Last Record Date
June 30, 2025
Outstanding Shares
4,340,000 shares
Float Size
14,460,000 shares
Short Percent of Float
0.91%
Today's Trading Volume
89,309 shares
Average Trading Volume
1,727,875 shares
Today's Volume Vs. Average
5%
Short Selling Virax Biolabs Group?
cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook

Sign up to receive the latest short interest report for Virax Biolabs Group and its competitors with MarketBeat's FREE newsletter.

Skip Charts & View Short Interest History

VRAX Short Interest Over Time

VRAX Days to Cover Over Time

VRAX Percentage of Float Shorted Over Time

Virax Biolabs Group Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
6/30/2025131,000 shares $103.71 thousand +529.8%0.9%1 $0.79
6/15/202520,800 shares $18.36 thousand -57.6%0.5%0.2 $0.88
5/31/202549,100 shares $46.65 thousand -55.9%1.2%0.3 $0.95
5/15/2025111,400 shares $118.08 thousand -23.2%2.8%0.6 $1.06
4/30/2025145,100 shares $142.23 thousand -43.9%3.6%0.6 $0.98
4/15/2025258,800 shares $274.33 thousand +85.9%6.4%1.1 $1.06
3/31/2025139,200 shares $158.69 thousand -12.2%3.4%0.6 $1.14
3/15/2025158,600 shares $217.28 thousand -21.7%3.9%0.4 $1.37
2/28/2025202,600 shares $338.34 thousand +12.3%5.0%0.5 $1.67
2/15/2025180,400 shares $343.54 thousand +205.8%4.5%0.5 $1.90
1/31/202559,000 shares $99.71 thousand -45.9%1.5%0.2 $1.69
1/15/2025109,000 shares $225.63 thousand -33.9%2.7%0.1 $2.07
12/31/2024164,900 shares $371.03 thousand +85.5%4.1%0.1 $2.25
12/15/202488,900 shares $139.57 thousand -38.5%2.2%0.1 $1.57
11/30/2024144,600 shares $284.86 thousand -49.1%3.6%0.1 $1.97
11/15/2024284,000 shares $508.36 thousand -36.4%7.0%0.1 $1.79
10/31/2024446,500 shares $924.26 thousand +92.6%11.0%0.1 $2.07
10/15/2024231,800 shares $394.06 thousand -9.2%5.7%0 $1.70
9/30/2024255,300 shares $495.28 thousand +45.4%6.3%0.1 $1.94
9/15/2024175,600 shares $454.80 thousand -72.2%4.3%0 $2.59
8/31/2024632,400 shares $2.95 million +142.7%15.6%0.1 $4.66
8/15/2024260,600 shares $362.23 thousand +1,278.8%12.6%0.1 $1.39
7/31/202418,900 shares $23.53 thousand -54.2%1.1%0 $1.25
7/15/202441,300 shares $46.67 thousand -36.6%2.4%0 $1.13
6/30/202465,100 shares $75.52 thousand -75.6%3.8%0 $1.16
6/15/2024266,800 shares $482.91 thousand +467.7%15.4%0.2 $1.81
5/31/202447,000 shares $55.46 thousand +7,733.3%2.7%0 $1.18
5/15/2024600 shares $476.10 -14.3%0.0%0 $0.79
4/30/2024700 shares $441.00 -94.2%0.0%0 $0.63
4/15/202412,000 shares $8.10 thousand +300.0%0.7%0.2 $0.68
3/31/20243,000 shares $2.15 thousand -80.9%0.2%0 $0.72
3/15/202415,700 shares $13.28 thousand -74.1%1.2%0.1 $0.85
2/29/202460,600 shares $58.33 thousand +9.2%4.6%0.4 $0.96
2/15/202455,500 shares $45.63 thousand -44.8%4.2%0.4 $0.82
1/31/2024100,500 shares $82.41 thousand +233.9%8.5%0.8 $0.82
1/15/202430,100 shares $31.00 thousand -78.3%2.6%0.4 $1.03
12/31/2023138,600 shares $202.36 thousand +6,500.0%7.7%1.9 $1.46
12/15/20232,100 shares $3.33 thousand -93.1%0.0%0 $1.59
11/30/202330,200 shares $7.02 thousand -39.8%0.3%0.2 $0.23
11/15/202350,200 shares $12.75 thousand -30.4%0.5%0.3 $0.25
Bitcoin Beats Gold — But This Coin Could Beat Them Both (Ad)

Bitcoin just hit a record high—but it’s not the top crypto play right now. Crypto analyst Juan Villaverde, who called Bitcoin’s breakout to $100K nearly to the day, says a lesser-known coin could be even bigger. It’s faster, cheaper, and backed by Google, Visa, and top VCs with over $200 million already invested.

Get the name of this “third pillar” crypto in Juan’s free report →
10/31/202372,100 shares $17.69 thousand -24.7%0.8%0.4 $0.25
10/15/202395,700 shares $28.33 thousand -24.1%1.0%0.6 $0.30
9/30/2023126,000 shares $40.95 thousand -32.9%1.4%0.7 $0.33
9/15/2023187,800 shares $67.89 thousand +476.1%2.0%1.1 $0.36
8/31/202332,600 shares $11.67 thousand +565.3%0.4%0.1 $0.36
8/15/20234,900 shares $1.89 thousand -80.3%0.1%0 $0.39
7/31/202324,900 shares $9.82 thousand -48.2%0.3%0.1 $0.39
7/15/202348,100 shares $19.20 thousand -68.9%0.5%0.2 $0.40
6/30/2023154,400 shares $60.20 thousand -46.2%1.7%0.3 $0.39
6/15/2023286,700 shares $117.20 thousand +42.2%3.1%0.5 $0.41
5/31/2023201,600 shares $78.97 thousand +0.6%3.2%0.4 $0.39
5/15/2023200,500 shares $70.40 thousand No Change3.1%0.1 $0.35

VRAX Short Interest - Frequently Asked Questions

What is Virax Biolabs Group's current short interest?

Short interest is the volume of Virax Biolabs Group shares that have been sold short but have not yet been closed out or covered. As of June 30th, traders have sold 131,000 shares of VRAX short. 0.91% of Virax Biolabs Group's shares are currently sold short. Learn More on Virax Biolabs Group's current short interest.

What is a good short interest ratio for Virax Biolabs Group?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. VRAX shares currently have a short interest ratio of 1.0. Learn More on Virax Biolabs Group's short interest ratio.

What is a good short interest percentage for Virax Biolabs Group?

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.91% of Virax Biolabs Group's floating shares are currently sold short.

Is Virax Biolabs Group's short interest increasing or decreasing?

Virax Biolabs Group saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 131,000 shares, an increase of 529.8% from the previous total of 20,800 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

What is Virax Biolabs Group's float size?

Virax Biolabs Group currently has issued a total of 4,340,000 shares. Some of Virax Biolabs Group's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Virax Biolabs Group currently has a public float of 14,460,000 shares.

How does Virax Biolabs Group's short interest compare to its competitors?

0.91% of Virax Biolabs Group's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Virax Biolabs Group: Lipocine Inc. (2.17%), Hoth Therapeutics, Inc. (4.53%), DURECT Corporation (2.84%), Edesa Biotech, Inc. (0.47%), VYNE Therapeutics Inc. (3.46%), Cyclacel Pharmaceuticals, Inc. (0.08%), Sonnet BioTherapeutics Holdings, Inc. (1.32%), ProPhase Labs, Inc. (2.93%), Carisma Therapeutics Inc. (4.97%), Mannatech, Incorporated (0.58%),

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($72.10 billion), Invesco QQQ ($26.89 billion), iShares Russell 2000 ETF ($19.61 billion), MicroStrategy Incorporated ($9.52 billion), iShares 20+ Year Treasury Bond ETF ($8.70 billion), WD-40 Company ($7.66 billion), Technology Select Sector SPDR Fund ($6.10 billion), Invesco S&P 500 Equal Weight ETF ($5.80 billion), Invesco S&P 500 Top 50 ETF ($5.53 billion), and Vanguard Large-Cap ETF ($5.35 billion). View all of the most shorted stocks.

What does it mean to sell short Virax Biolabs Group stock?

Short selling VRAX is an investing strategy that aims to generate trading profit from Virax Biolabs Group as its price is falling. VRAX shares are trading down $0.02 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Virax Biolabs Group?

A short squeeze for Virax Biolabs Group occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of VRAX, which in turn drives the price of the stock up even further.

How often is Virax Biolabs Group's short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including VRAX, twice per month. The most recent reporting period available is June, 30 2025.




This page (NASDAQ:VRAX) was last updated on 7/24/2025 by MarketBeat.com Staff
From Our Partners